DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Ovarian Transitional Cell Carcinoma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian Transitional Cell Carcinoma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian transitional cell carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
CREB binding lysine acetyltransferase (CREBBP) — CREBBP is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1vudrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9H0K · 1.75 Å · ligand propionyl Coenzyme A (1VU). Experimental structure, not a prediction.
What the evidence adds up to
A 1990 case series identified primary ovarian transitional cell carcinoma as a distinct histologic type, separate from other epithelial ovarian cancers, but provided no treatment data or survival statistics for the subtype. The paper focused on diagnostic criteria and noted that prognosis could not be reliably assessed from the small number of cases then available.
A 2006 review emphasised that epithelial ovarian cancer is a heterogeneous group of neoplasms, each with different underlying molecular genetic events. High-grade serous carcinoma, the most common type, was described as developing de novo from ovarian surface epithelium or cortical inclusion cysts, while mucinous and low-grade serous cancers followed an adenoma-carcinoma sequence. The review anticipated that recognising these distinct molecular pathways would lead to type-specific therapies, but no such agents were tested or recommended in the paper.
A 2016 review proposed a four-step model for ovarian cancer development—migration to the ovaries, seeding, dormant cancer stage, and tumour expansion—linked to hormonal changes during reproductive age and menopause. The authors argued that understanding these steps is critical for early detection markers and personalised prevention, but again offered no drug or clinical trial data. No abstract addressed treatment of ovarian transitional cell carcinoma specifically.
What is still missing is any clinical trial testing a drug against ovarian transitional cell carcinoma, any molecular profiling that distinguishes this subtype from other ovarian cancers at the actionable level, and any patient stratification strategy that would allow a repurposing study to be designed. Without a defined target, a validated biomarker, or a funded clinical cohort, the subtype remains a histologic curiosity with no evidence base for drug repurposing.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Endocrine Related Cancer · 2016 · 32 citations · open access
Redefining the origin and evolution of ovarian cancer: a hormonal connection
AbstractOvarian cancer has the highest mortality of all female reproductive cancers. Late diagnosis, tumour heterogeneity and the development of chemoresistance contribute to this statistic and work against patient survival. Current studies have revealed novel concepts that impact our view on how ovarian cancer develops. The greatest impact is on our understanding that, as a disease, ovarian cancer has multiple cellular origins and that these malignant precursors are mostly derived from outside of the ovaries. In this review, we propose a new concept of a step-wise developmental process that may underwrite ovarian tumorigenesis and progression: (1) migration/recruitment to the ovaries; (2) seeding and establishment in the ovaries; (3) induction of a dormant cancer stage; and (4) expansion and tumor progression. We will discuss the relationship of each step with the changing ovarian function and milieu during the reproductive age and the subsequent occurrence of menopause. The realization that ovarian cancer development and progression occurs in distinct steps is critical for the search of adequate markers for early detection that will offer personalized strategies for prevention and therapy.
Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data.
AbstractOvarian carcinoma is the most lethal gynaecological malignancy, most tumours being advanced at presentation. However, little is known about precursor lesions and the cell of origin of epithelial ovarian malignancy. In this review, the proposed cell of origin is discussed as well as recent molecular data relating to ovarian cancers of different morphological types. It is stressed that ovarian carcinoma is a heterogeneous group of neoplasms with several different morphological types, each with their own underlying molecular genetic events. Recent data suggest that mucinous ovarian cancers and a small subset of serous cancers (low grade ovarian serous carcinoma) develop through a well-defined adenoma-carcinoma sequence while the much more common high grade ovarian serous carcinoma develops de novo from the ovarian surface epithelium or the epithelium of cortical inclusion cysts. The realisation that various morphological types of epithelial ovarian cancer are associated with different molecular genetic events is a major advance in the study of ovarian cancer. It can be anticipated that this will lead to the development of specific therapeutic agents of value against a specific tumour type.
American Journal of Clinical Pathology · 1990 · 4 citations
Primary Ovarian Transitional Cell Carcinoma: Diagnostic and Prognostic Considerations
AbstractJournal Article Primary Ovarian Transitional Cell Carcinoma: Diagnostic and Prognostic Considerations Get access Deborah J. Gersell, M.D. Deborah J. Gersell, M.D. Department of Pathology Washington University School of Medicine St. Louis, Missouri Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 93, Issue 4, 1 April 1990, Pages 586–588, https://doi.org/10.1093/ajcp/93.4.586 Published: 01 April 1990
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
